Use of leptin-conjugated phosphatidic acid liposomes with resveratrol and epigallocatechin gallate to protect dopaminergic neurons against apoptosis for Parkinson's disease therapy
- PMID: 33189953
- DOI: 10.1016/j.actbio.2020.11.015
Use of leptin-conjugated phosphatidic acid liposomes with resveratrol and epigallocatechin gallate to protect dopaminergic neurons against apoptosis for Parkinson's disease therapy
Abstract
Complex liposomes were assembled with 1,2-distearoyl-sn-glycero-3-phosphocholine, dihexadecyl phosphate (DHDP), cholesterol and 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphate (PA) to act as drug carriers for resveratrol (RES) and epigallocatechin gallate (EGCG). The liposomes were modified with leptin (Lep) on the surface to cross the blood-brain barrier (BBB) and to rescue degenerated dopaminergic neurons. The activity of RES and EGCG against neurotoxicity was investigated using an in vitro neurodegenerative model established by SH-SY5Y cells with an insult of 1-methyl-4-phenylpyridinium (MPP+). The results indicated that increasing the mole percentage of DHDP and PA increased the particle size and absolute zeta potential value, and improved the entrapment efficiency of RES and EGCG; however, this increase reduced the release rate of RES and EGCG and the grafting efficiency of Lep. The ability of Lep/RES-EGCG-PA-liposomes to cross the BBB was found to be higher than that of non-modified liposomes. Further, the addition of PA and Lep into liposomes enhanced cell viability and target efficiency. The immunofluorescence results demonstrated that the conjugation of Lep with liposomes enabled the docking of HBMECs and SH-SY5Y cells via Lep receptor, and enhanced their ability to permeate the BBB and cellular uptake. Immunofluorescence and western blot analysis also revealed that RES and EGCG encapsulated into liposomes could be a neural defensive strategy by reducing the apoptosis promotor protein Bcl-2 associated X protein and α-synuclein, and enhancement in the apoptosis inhibitor protein B cell lymphoma 2, tyrosine hydroxylase, and the dopamine transporter. Hence, Lep-PA-liposomes can be an excellent choice of potential delivery system for PD treatment.
Keywords: Parkinson's disease; apoptosis; leptin; liposome; phosphatidic acid.
Copyright © 2020. Published by Elsevier Ltd.
Conflict of interest statement
Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Similar articles
-
Astragaloside IV- and nesfatin-1-encapsulated phosphatidylserine liposomes conjugated with wheat germ agglutinin and leptin to activate anti-apoptotic pathway and block phosphorylated tau protein expression for Parkinson's disease treatment.Mater Sci Eng C Mater Biol Appl. 2021 Oct;129:112361. doi: 10.1016/j.msec.2021.112361. Epub 2021 Aug 9. Mater Sci Eng C Mater Biol Appl. 2021. PMID: 34579880
-
Glutathione Liposomes Carrying Ceftriaxone, FK506, and Nilotinib to Control Overexpressed Dopamine Markers and Apoptotic Factors in Neurons.ACS Biomater Sci Eng. 2021 Jul 12;7(7):3242-3255. doi: 10.1021/acsbiomaterials.1c00555. Epub 2021 Jun 30. ACS Biomater Sci Eng. 2021. PMID: 34189904
-
A Poloxamer-407 modified liposome encapsulating epigallocatechin-3-gallate in the presence of magnesium: Characterization and protective effect against oxidative damage.Int J Pharm. 2018 Dec 1;552(1-2):225-234. doi: 10.1016/j.ijpharm.2018.10.004. Epub 2018 Oct 3. Int J Pharm. 2018. PMID: 30291957
-
Epigallocatechin-3-gallate: A phytochemical as a promising drug candidate for the treatment of Parkinson's disease.Front Pharmacol. 2022 Sep 12;13:977521. doi: 10.3389/fphar.2022.977521. eCollection 2022. Front Pharmacol. 2022. PMID: 36172194 Free PMC article. Review.
-
Resveratrol Brain Delivery for Neurological Disorders Prevention and Treatment.Front Pharmacol. 2018 Nov 20;9:1261. doi: 10.3389/fphar.2018.01261. eCollection 2018. Front Pharmacol. 2018. PMID: 30524273 Free PMC article. Review.
Cited by
-
Nanoencapsulation of general anaesthetics.Nanoscale Adv. 2024 Feb 15;6(5):1361-1373. doi: 10.1039/d3na01012k. eCollection 2024 Feb 27. Nanoscale Adv. 2024. PMID: 38419874 Free PMC article. Review.
-
Single-particle imaging of nanomedicine entering the brain.Proc Natl Acad Sci U S A. 2024 Jan 30;121(5):e2309811121. doi: 10.1073/pnas.2309811121. Epub 2024 Jan 22. Proc Natl Acad Sci U S A. 2024. PMID: 38252832
-
The Therapeutic Potential of Natural Dietary Flavonoids against SARS-CoV-2 Infection.Nutrients. 2023 Aug 3;15(15):3443. doi: 10.3390/nu15153443. Nutrients. 2023. PMID: 37571380 Free PMC article. Review.
-
Conjugation, Prodrug, and Co-Administration Strategies in Support of Nanotechnologies to Improve the Therapeutic Efficacy of Phytochemicals in the Central Nervous System.Pharmaceutics. 2023 May 23;15(6):1578. doi: 10.3390/pharmaceutics15061578. Pharmaceutics. 2023. PMID: 37376027 Free PMC article. Review.
-
Regulatory Basis of Adipokines Leptin and Adiponectin in Epilepsy: from Signaling Pathways to Glucose Metabolism.Neurochem Res. 2023 Jul;48(7):2017-2028. doi: 10.1007/s11064-023-03891-2. Epub 2023 Feb 16. Neurochem Res. 2023. PMID: 36797447 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous
